BGM0504
Bioequivalence Study of BGM0504 Injection
BrightGene Bio-Medical Technology Co · Phase 1 · Completed · Enrollment 144
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| BGM0504 Injection multi-dose pen | n/r | n/r | n/r | n/r |
| BGM0504 Injection single-dose pen | n/r | n/r | n/r | n/r |
| BGM0504 Injection single-dose pen-2 | n/r | n/r | n/r | n/r |
Not shown
- BGM0504 Injection multi-dose pen: endpoint not reported
- BGM0504 Injection single-dose pen: endpoint not reported
- BGM0504 Injection single-dose pen-2: endpoint not reported